SESSION TITLE: Fellow Case Report Poster - Diffuse Lung Disease I SESSION TYPE: Affiliate Case Report Poster PRESENTED ON: Tuesday, October 25, 2016 at 01:30 PM - 02:30 PM INTRODUCTION: Adalimumab (TNF Inhibitor) has been available since 2008 for the treatment of various autoimmune diseases. Despite clinical efficacy, many TNF inhibitors have a considerable side effect profile. There have been numerous case reports outlining the pulmonary side effects of adalimumab including, but not limited to, interstitial pneumonia, fibrosing alveolitis, and granulomatous pneumonitis. Here we present a case of a small size vessel pulmonary vasculitis attributed to adalimumab. We believe it is the first such case described. CASE PRESENTATION: 72 YO male who was diagnosed with Ulcerative Colitis in 2009, failed azathioprine and mesalamine. Started on Adalimumab 40mg subcutaneously every other week which was then increased to weekly injections that led to remission. Following the initiation of adalimumab, the patient started complaining of hemoptysis. CT chest showed progressive interstitial thickening, ground-glass opacities in both lungs, predominantly involving the middle lobe, lingua and both lower lobes. There was relatively mild stable architectural distortion and mild traction bronchiectasis. Due to the progression of disease seen on CT, the patient underwent a bronchoscopy which showed blood in the trachea and chronic bronchitic changes, however the bronchoscopist was unable to identify a source of bleeding. A work up that included autoimmune/vasculitis panel was negative. Due to his ongoing hemoptysis, he underwent a video assisted thoracoscopy which showed extensive fibrin thrombi involving microvascular bed and small caliber arteries. DISCUSSION: As his symptoms started shortly after initiating adalimumab, the findings were suspected to be related to adalimumab. Adalimumab was subsequently discontinued, and as a result the patient's cough and hemoptysis resolved within a few weeks. CONCLUSIONS: Hemoptysis can be attributed to many causes and therefore a thorough history is essential in narrowing an expansive differential diagnosis. It is imperative to realize that even if a medication has not caused a disease process previously if the history leads you towards that particular pathway, it is the practitioner's responsibility to follow the clues towards an answer. Irrespective of how old a medication may be there are always new ways a patient may react. Reference #1: http://www.pneumotox.com/search/results/56f1d7f1a8ac6/ Reference #2: Lauque D, Cadranel J, et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Medicine (Baltimore). 2000 Jul. 79(4):222-33. [Medline]. DISCLOSURE: The following authors have nothing to disclose: Kumar Shah, Randolph Lipchik, Rose Franco No Product/Research Disclosure Information
Read full abstract